Abdominal obesity and metabolic syndrome, Nature, vol.322, issue.7121, pp.881-887, 2006. ,
DOI : 10.1038/nature05488
Obesity, The Lancet, vol.366, issue.9492, pp.1197-1209, 2005. ,
DOI : 10.1016/S0140-6736(05)67483-1
Abnormal Lipid and Glucose Metabolism in Obesity: Implications for Nonalcoholic Fatty Liver Disease, Gastroenterology, vol.132, issue.6, pp.2191-2207, 2007. ,
DOI : 10.1053/j.gastro.2007.03.055
Obesity is associated with macrophage accumulation in adipose tissue, Journal of Clinical Investigation, vol.112, issue.12, pp.1796-1808, 2003. ,
DOI : 10.1172/JCI19246DS1
Inflammation and metabolic disorders, Nature, vol.314, issue.7121, pp.860-867, 2006. ,
DOI : 10.1038/nature05485
Obesity, Inflammation, and Insulin Resistance, Gastroenterology, vol.132, issue.6, pp.2169-2180, 2007. ,
DOI : 10.1053/j.gastro.2007.03.059
Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance, Journal of Clinical Investigation, vol.112, issue.12, pp.1821-1830, 2003. ,
DOI : 10.1172/JCI19451DS1
Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice, Journal of Clinical Investigation, vol.117, issue.10, pp.2877-2888, 2007. ,
DOI : 10.1172/JCI31986DS1
Elevated Expression of Osteopontin May Be Related to Adipose Tissue Macrophage Accumulation and Liver Steatosis in Morbid Obesity, Diabetes, vol.58, issue.1, pp.125-133, 2009. ,
DOI : 10.2337/db08-0400
URL : https://hal.archives-ouvertes.fr/hal-00419058
Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice, Journal of Clinical Investigation, vol.118, issue.3, pp.829-838, 2008. ,
DOI : 10.1172/JCI34275
Targeting the endocannabinoid system: to enhance or reduce?, Nature Reviews Drug Discovery, vol.1761, issue.5, pp.438-455, 2008. ,
DOI : 10.1038/sj.bjp.0706971
Endocannabinoids and Liver Disease. I. Endocannabinoids and their receptors in the liver, AJP: Gastrointestinal and Liver Physiology, vol.294, issue.1, pp.9-12, 2008. ,
DOI : 10.1152/ajpgi.00467.2007
The Endocannabinoid System as an Emerging Target of Pharmacotherapy, Pharmacological Reviews, vol.58, issue.3, pp.389-462, 2006. ,
DOI : 10.1124/pr.58.3.2
Endocannabinoids and Liver Disease. IV. Endocannabinoid involvement in obesity and hepatic steatosis, AJP: Gastrointestinal and Liver Physiology, vol.294, issue.5, pp.1101-1104, 2008. ,
DOI : 10.1152/ajpgi.00057.2008
Cannabinoid-based drugs as anti-inflammatory therapeutics, Nature Reviews Immunology, vol.267, issue.5, pp.400-411, 2005. ,
DOI : 10.1002/glia.10177
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice, Nature Medicine, vol.434, pp.782-786, 2005. ,
CB2 receptors as new therapeutic targets for liver diseases, British Journal of Pharmacology, vol.171, issue.2, pp.286-289, 2008. ,
DOI : 10.1038/sj.bjp.0707511
Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury, The FASEB Journal, vol.21, issue.8, pp.1788-1800, 2007. ,
DOI : 10.1096/fj.06-7451com
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228252
Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor, European Journal of Pharmacology, vol.396, issue.2-3, pp.141-149, 2000. ,
DOI : 10.1016/S0014-2999(00)00211-9
Utilisation of the method of Kalman filtering for performing the on-line computation of background metabolism in the free-moving, free-feeding rat, Physiology & Behavior, vol.49, issue.1, pp.177-187, 1991. ,
DOI : 10.1016/0031-9384(91)90252-J
Practical aspects of indirect calorimetry in laboratory animals, Neuroscience & Biobehavioral Reviews, vol.18, issue.3, pp.435-447, 1994. ,
DOI : 10.1016/0149-7634(94)90056-6
Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage, Journal of Clinical Investigation, vol.115, issue.12, pp.3554-3563, 2005. ,
DOI : 10.1172/JCI25764
Antifibrogenic role of the cannabinoid receptor CB2 in the liver, Gastroenterology, vol.128, issue.3, pp.742-755, 2005. ,
DOI : 10.1053/j.gastro.2004.12.050
3-(1???,1???-Dimethylbutyl)-1-deoxy-??8-THC and related compounds: synthesis of selective ligands for the CB2 receptor, Bioorganic & Medicinal Chemistry, vol.7, issue.12, pp.2905-2914, 1999. ,
DOI : 10.1016/S0968-0896(99)00219-9
The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy, The FASEB Journal, vol.23, issue.7, 2009. ,
DOI : 10.1096/fj.09-129478
URL : https://hal.archives-ouvertes.fr/inserm-00371859
AM630, a competitive cannabinoid receptor antagonist, Life Sciences, vol.56, issue.23-24, pp.1949-1955, 1995. ,
DOI : 10.1016/0024-3205(95)00175-6
Overexpression of Monocyte Chemoattractant Protein-1 in Adipose Tissues Causes Macrophage Recruitment and Insulin Resistance, Journal of Biological Chemistry, vol.281, issue.36, pp.26602-26614, 2006. ,
DOI : 10.1074/jbc.M601284200
MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity, Journal of Clinical Investigation, vol.116, issue.6, pp.1494-1505, 2006. ,
DOI : 10.1172/JCI26498DS1
Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes, Histochemistry and Cell Biology, vol.346, issue.1, pp.177-187, 2006. ,
DOI : 10.1007/s00418-005-0127-4
Regulation, Function, and Dysregulation of Endocannabinoids in Models of Adipose and ??-Pancreatic Cells and in Obesity and Hyperglycemia, The Journal of Clinical Endocrinology & Metabolism, vol.91, issue.8, pp.3171-3180, 2006. ,
DOI : 10.1210/jc.2005-2679
receptor-mediated migration of immune cells: it can go either way, British Journal of Pharmacology, vol.6, issue.2, pp.299-308, 2008. ,
DOI : 10.1038/sj.bjp.0707523
CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways, AJP: Heart and Circulatory Physiology, vol.294, issue.3, pp.1145-1155, 2008. ,
DOI : 10.1152/ajpheart.01328.2007
Genomic and Functional Changes Induced by the Activation of the Peripheral Cannabinoid Receptor CB2 in the Promyelocytic Cells HL-60. POSSIBLE INVOLVEMENT OF THE CB2 RECEPTOR IN CELL DIFFERENTIATION, Journal of Biological Chemistry, vol.275, issue.21, pp.15621-15628, 2000. ,
DOI : 10.1074/jbc.275.21.15621
Effects of cannabinoid receptors on skeletal muscle oxidative pathways, Molecular and Cellular Endocrinology, vol.267, issue.1-2, pp.63-69, 2007. ,
DOI : 10.1016/j.mce.2006.12.038
Endocannabinoid Dysregulation in the Pancreas and Adipose Tissue of Mice Fed With a High-fat Diet, Obesity, vol.15, issue.3, pp.553-565, 2008. ,
DOI : 10.1038/oby.2007.106
Cannabinoid receptors regulate Ca2+ signals and insulin secretion in pancreatic ??-cell, Cell Calcium, vol.39, issue.2, pp.155-162, 2006. ,
DOI : 10.1016/j.ceca.2005.10.005
CCR2 modulates inflammatory and metabolic effects of high-fat feeding, Journal of Clinical Investigation, vol.116, issue.5, pp.115-124, 2006. ,
DOI : 10.1172/JCI24335C1
Activation of the Peripheral Endocannabinoid System in Human Obesity, Diabetes, vol.54, issue.10, pp.2838-2843, 2005. ,
DOI : 10.2337/diabetes.54.10.2838
Identification of Endocannabinoids and Related Compounds in Human Fat Cells*, Obesity, vol.173, issue.4, pp.837-845, 2007. ,
DOI : 10.1016/j.cyto.2006.06.005
Dysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal Obesity, Diabetes, vol.55, issue.11, pp.3053-3060, 2006. ,
DOI : 10.2337/db06-0812
Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men, Int J Obes (Lond), vol.31, pp.692-699, 2007. ,
Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats, Hepatology, vol.330, issue.1, pp.122-129, 2007. ,
DOI : 10.1002/hep.21641
Paracrine Activation of Hepatic CB1 Receptors by??Stellate Cell-Derived Endocannabinoids Mediates??Alcoholic Fatty Liver, Cell Metabolism, vol.7, issue.3, pp.227-235, 2008. ,
DOI : 10.1016/j.cmet.2007.12.007
Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases, Current Opinion in Pharmacology, vol.6, issue.6, pp.586-591, 2006. ,
DOI : 10.1016/j.coph.2006.09.001
68 Daily cannabis smoking as a risk factor for fibrosis progression in chronic hepatitis C, Journal of Hepatology, vol.40, pp.63-71, 2005. ,
DOI : 10.1016/S0168-8278(04)90068-2
CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis, Nature Medicine, vol.30, issue.6, pp.671-676, 2006. ,
DOI : 10.1038/nm1421
Daily Cannabis Use: A Novel Risk Factor of Steatosis Severity in Patients With Chronic Hepatitis C, Gastroenterology, vol.134, issue.2, pp.432-439, 2008. ,
DOI : 10.1053/j.gastro.2007.11.039
Endocannabinoids as novel mediators of liver diseases, Journal of Endocrinological Investigation, vol.29, pp.58-65, 2006. ,